TCGRx launches LocalRx with telepharmacy offering
TCGRx is taking the wraps off LocalRx, a new product line that expedites the will call process for prescription medications and includes a telepharmacy consultation option for patients via webcam and telephone.
LocalRx also is managing to return to stock, produce detailed reports on kiosk inventory levels and all other activity and offers pharmacies remote monitoring of pick-ups and full or empty slots, variable locker sizes, and a search and seize function.
Patients will receive automated notification, via e-mail or text message, that their prescriptions have been filled. Patient retrieval is handled via pick-up code or smartphone app. LocalRx also offers a touchscreen interface, barcode authentication, multiple drawer configurations, and audit trail reporting.
In addition, LocalRx OTC will enable pharmacies to stock OTCs such as aspirin, cold medicine, and eye drops. When customers pick up their pharmacy scripts from the LocalRx machine, they can access the OTC machine and pay for all of these items without having to stand on line at the pharmacy.
“We see it as a path to improve customer service during our customers’ busiest times, while also facilitating prescription pickup when the pharmacy is closed. By providing the pharmacy industry with the LocalRx solutions, we can now offer total pick-up convenience, precisely when and where our pharmacies and their customers need it,” Duane Chudy, TCGRx’s executive of the board, said.
Catalent acquires Juniper Pharmaceuticals
Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is acquiring Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division.
The acquisition of Juniper will expand Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network, the company said.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” Catalent Oral Drug Delivery president Jonathan Arnold said. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
Catalent will continue to support Juniper’s Crinone (progesterone gel) franchise marketed by Merck KGaA outside of the U.S. Juniper’s Intravaginal Ring development pipeline was previously licensed to Daré Bioscience, and Catalent will not be involved in the further development of this program.
Merz’s Xeomin for adults gets FDA approval
Merz North America has received the green light from the Food and Drug Administration for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. The condition can occur from difficulty retaining saliva inside the mouth, issues with swallowing and from problems controlling facial muscles.
Xeomin is the first and only neurotoxin with this approved indication in the United States.
“Until now, there has not been an FDA approved treatment for this debilitating condition,” Merz vice president and U.S. head of neurosciences Kevin O’Brien, said. “This approval represents a significant milestone in addressing the unmet needs for more than 600,000 adults who suffer from chronic sialorrhea, and underscores our commitment to improving the lives of those living with movement disorders.”
Sialorrhea is a common symptom among patients who suffer from neurological disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), cerebral palsy (CP) or who have experienced a stroke.
This is the fourth neurological indication for Xeomin, which was first approved by the FDA in 2010 for the treatment of cervical dystonia and blepharospasm in patients previously treated with onabotulinumtoxinA, and in adult patients and in 2015 for upper limb spasticity in adult patients.